Drug intelligence / Profile preview

ARC-102

Development stage: Preclinical
Lead developer: Third Arc Bio
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

ARC-102 is a Bispecific T-cell Engager (BiTE) developed by Third Arc Bio, Inc. It functions as a CD3 stimulant, targeting the T cell surface glycoprotein CD3. This investigational drug is currently in preclinical development for various oncological indications, including Endometrial Carcinoma, Lung Cancer, and Ovarian Cancer.

Targets

CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on ARC-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARC-102.

Explore the full profile